

# The *PROTECTION*<sup>®</sup> Program


Program of Research to show Telmisartan End-organ protection

- A cardio & vascular trial program aimed at showing the potential of telmisartan to protect against end-organ damage caused by hypertension, in all stages of the CV continuum
- 10 clinical studies, 6 875 patients, 32 countries
- Includes special patient populations such as those with type 2 diabetes & hypertension, renal impairment with albuminuria, & obese subjects with hypertension

The sponsor of the PROTECTION<sup>®</sup> trial program is Boehringer Ingelheim, the co-funders in selected countries are Bayer Schering Pharma and GlaxoSmithKline.



# The **PROTECTION** Program Continuum



Adapted from Dzau, Braunwald. Am Heart J 1991;121:1244-1263

The sponsor of the PROTECTION<sup>®</sup> trial program is Boehringer Ingelheim, the co-funders in selected countries are Bayer Schering Pharma and GlaxoSmithKline.



# The **PROTECTION** Program

Study name	Subject	Comparator
<b>Protection in at-risk patient populations</b>		
<b>PRISMA I &amp; II</b>	Early morning blood pressure	Ramipril
<b>ARBs FDC</b>	Early morning blood pressure	Losartan/HCTZ
<b>ATHOS</b>	Early morning blood pressure in elderly patient with ISH	Amlodipine/HCTZ
<b>SMOOTH</b>	Early morning blood pressure in overweight/obese hypertensive patients with type 2 diabetes	Valsartan/HCTZ
<b>Renal protection</b>		
<b>TRENDY</b>	Renal endothelial dysfunction	Ramipril
<b>DETAIL</b>	Early nephropathy	Enalapril
<b>INNOVATION</b>	Incipient to overt nephropathy	Placebo
<b>AMADEO</b>	Overt nephropathy	Losartan
<b>VIVADI</b>	Overt nephropathy	Valsartan

The sponsor of the PROTECTION® trial program is Boehringer Ingelheim, the co-funders in selected countries are Bayer Schering Pharma and GlaxoSmithKline.